FDA Phone Call Preceded Untitled Letter To Lilly Over Amyvid
This article was originally published in The Pink Sheet Daily
Lilly promised to remove offending images from promotional materials for its imaging product, but the agency followed up with a “notice of violation” letter two months later anyway.
You may also be interested in...
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.